Vivos Therapeutics Inc (VVOS): 4.53s

Play Episode

8min

Proactive - Interviews for investors

Time Finance CEO on Q3 update: record lending & growth to resilient small businesses

Time Finance PLC (AIM:TIME) CEO Ed Rimmer takes Proactive's Stephen Gunnion through the company’s performance in the third quarter, highlighting a record gross lending book and improved arrears management. Rimmer explained that Time Finance provides funding solutions to small businesses, including invoice finance, asset finance, and secured loans, typically supporting businesses with turnover up to £10 million. He said, “We help businesses grow, but we also help businesses to survive as well.” The company’s lending book reached a record £210 million at the end of February, with arrears falling to 5% from 6% a year earlier. Rimmer noted this progress came despite challenging market conditions and was achieved without compromising credit quality. Margins have also increased, with profit margins now at 40%. This was attributed to tight cost control and improved efficiency, including leveraging technology and streamlining internal processes. Time Finance has not increased its headcount significantly post-COVID, which has helped support margin growth. Rimmer also addressed the broader economic environment, pointing to interest rate pressures, inflation, and increased insolvencies, but emphasised that small businesses remain resilient. The company sees opportunity as traditional banks become more risk-averse, creating space for independent lenders. Visit Proactive’s YouTube channel for more interviews like this. Don’t forget to like the video, subscribe to the channel, and enable notifications so you never miss an update. #TimeFinance #SMElending #AlternativeFinance #BusinessLoans #InvoiceFinance #AssetFinance #Q3TradingUpdate #IndependentLender #FinancialResults #SmallBusinessFinance

Proactive - Interviews for investors

Nextech3D.ai disrupts industry with launch of AI-powered Ecommerce content studio

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to announce the launch of a new AI-powered feature as part of the company’s Ecommerce AI Studio. The platform utilizes generative AI to create photorealistic lifestyle images and videos of products—such as apparel, accessories, and furniture—being worn, held, or displayed in realistic settings, eliminating the need for traditional photography. Gappelberg highlighted that ToggleStudios, Nextech3D.ai’s AI-driven content creation tool, is designed to help online retailers generate lifestyle content at scale. The platform reduces reliance on costly and time-consuming physical photoshoots, enabling faster content production, lower operating costs, and increased visual output. The new feature will allow users to generate AI-rendered images of apparel on virtual models with varied backgrounds and appearances. Additionally, retailers can visualize accessories, electronics, and other items in realistic usage scenarios, enhancing product presentation for e-commerce. Another major upgrade is the automated generation of product videos and interactive 3D visuals. Using advanced AI, the system simulates lighting, texture, and perspective, ensuring high-quality imagery that closely replicates traditional photography—but in less time and at a lower cost. #nextech3d.al #otcqx #nexcf #cse #ntar #EvanGappelberg #AmazonSellerCentral #3DModeling #AIPhotography #EcommerceInnovation #3DTechnology #LifestylePhotography #ProactiveInterviews #TechInnovation #AmazonPartners#proactiveinvestors #nextech3d.al

Proactive - Interviews for investors

Nevis Brands doubles revenue in 2024, cuts losses & expands in key Markets

Nevis Brands CEO John Kueber joined Steve Darling from Proactive to discuss the company’s financial results for fiscal year 2024 and the fourth quarter ending November 30, 2024. Nevis reported $1.56 million in revenue, more than doubling its 2023 sales as it expanded into new markets and introduced new cannabis products. The company narrowed its net loss to approximately $362,000, down from $400,000 the previous year. When excluding interest, depreciation, and amortization, the adjusted loss was reduced to about $58,000. Nevis maintained its leading position in Washington’s cannabis beverage market and achieved the second-best sales ranking in Missouri within its first year in that state. The company also made significant progress in debt reduction, cutting current liabilities from $1.12 million to about $573,000 through debt payments and restructuring. Looking ahead to 2025, Nevis expects continued growth driven by expanding sales of its Happy Apple and Major brands in the hemp-derived THC beverage market. The company also looking for market re-entry in Ohio and Arizona following previous licensing and market shifts. All this happening while the company focused on licensing established products in key markets. Kueber acknowledged that the fourth quarter was challenging, with revenue declines due to licensing and market shifts in Arizona, Ohio, Oregon, and California. However, growth in New Jersey and Missouri helped offset these declines, and the company remains focused on long-term expansion and profitability. #proactiveinvestors #nevisbrandsinc #cse #nevi #otcqb #nevif #majorbrand #cannabis #CannabisInvesting #THCDrinks #HappyApple #CannabisStocks #HempTHC #CannabisBeverages #InvestorUpdate #JohnKueber #CannabisNews #CannabisRevenue #DebtReduction #ProactiveInvestors

Proactive - Interviews for investors

OKYO Pharma achieves key stability milestone for Urcosimod in clinical development

OKYO Pharma CEO Gary Jacob joined Steve Darling from Proactive to share a significant advancement in the company’s ongoing drug development efforts. The company has successfully demonstrated that urcosimod—formerly known as OK-101—remains stable for more than two and a half years in single-use ampoules, which are used for patient administration. This milestone is a crucial step forward in ensuring the long-term viability of the drug as it progresses through clinical trials. Urcosimod is currently being evaluated in a Phase 2b clinical trial, which is a randomized, placebo-controlled, double-masked study involving 48 patients. The trial is focused on assessing the drug’s effectiveness in treating neurotrophic keratopathy (NCP), a serious and progressive degenerative eye disease. Jacob emphasized that achieving success in clinical development extends beyond obtaining positive clinical trial data. A crucial aspect of regulatory approval includes meeting the rigorous Chemistry, Manufacturing, and Controls (CMC) requirements set by the U.S. Food and Drug Administration (FDA). By demonstrating long-term stability, OKYO Pharma has strengthened its regulatory submission package, addressing an essential factor in the drug’s future approval and commercialization. The company recently completed Good Manufacturing Practice (GMP) stability assay testing of single-use ampoules containing urcosimod in an ophthalmic solution. The results were highly promising—ampoules stored under refrigerated conditions maintained stability for over two and a half years, while initial three-month data from samples stored at room temperature showed potency levels at or above 100%. These findings reinforce confidence in urcosimod’s shelf life and its potential for real-world clinical use. As OKYO Pharma continues to advance urcosimod through the regulatory and clinical development process, this stability milestone represents a critical achievement in its journey toward providing an effective tr

Followers	97
Posts	10158
Boards Moderated	0
Alias Born	03/29/2010

Volume:	50,056
Day Range:	2.4202 - 2.65
Bid:	2.55
Ask:	2.58
Last Trade Time:	7:50:08 PM EDT
Total Trades:	386

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

VVOS Detailed Quote

Recent VVOS News

More VVOS News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent VVOS News

Go Ad-Free